NEWS
PRESS CENTER
2024
2024-04-15
- In Q2, Obtained IND approval of LAE102(ActRIIA mAb) for the treatment of obesity from FDA and CDE
- In May, First patient enrolled in AFFIRM-205, a phase III clinical study of LAE002 (afuresertib) plus fulvestrant for the treatment of breast cancer
- In June, First subject dosed in phase I clinical trial of LAE102 for the treatment of obesity
- In Sep, Announced robust phase 1b data of LAE002 for breast cancer at ESMO
- In Oct, Initiated subcutaneous dosing cohort of LAE102 phase I SAD study for obesity in China
- In November, Entered into a clinical collaboration agreement with Eli Lilly of LAE102 for obesity in the U.S.
- In December, Completed LAE102 Phase I SAD study for obesity in China with positive results
Recommendation
-
2024-11-20Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of ObesityMore -
2024-06-26Laekna Announces First Subject Dosed in Phase I Clinical Trial of LAE102 (a monoclonal antibody against ActRIIA) in China for The Treatment of ObesityMore
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
Follow us on Linkedin
Copyright © Laekna Therapeutics, All Rights Reserved. 沪ICP备17047795号 Privacy Policy
